Pulmonary Hypertension Complicating Connective Tissue Disease

Elizabeth R. Volkmann; Augustine Chung; Rajan Saggar; John A. Belperio; Joseph P. Lynch III

doi:10.1055/s-0037-1606203

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2017; 38(05): 619-635
DOI: 10.1055/s-0037-1606203

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pulmonary Hypertension Complicating Connective Tissue Disease

Elizabeth R. Volkmann^*

¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

,

Augustine Chung^*

²Division of Pulmonary, Critical Care Medicine, Clinical Immunology, and Allergy, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

,

Rajan Saggar

²Division of Pulmonary, Critical Care Medicine, Clinical Immunology, and Allergy, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

,

John A. Belperio

²Division of Pulmonary, Critical Care Medicine, Clinical Immunology, and Allergy, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

,

Joseph P. Lynch III

²Division of Pulmonary, Critical Care Medicine, Clinical Immunology, and Allergy, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

› Author Affiliations

Abstract

Pulmonary hypertension (PH) may complicate connective tissue disease (CTD; particularly systemic sclerosis [scleroderma]), and is associated with increased mortality. More than 70% of cases of PH complicating CTD occur in patients with systemic sclerosis (SSc), which is the major focus of this article. Pulmonary complications (i.e., interstitial lung disease [ILD] and PH) are the leading causes of SSc-related deaths. “Isolated” PH (i.e., without ILD) complicates SSc in 7.5 to 20% of cases; secondary PH may also occur in patients with SSc-associated ILD. Several clinical markers and specific autoantibody profiles have been associated with PH in SSc. The role of PH-specific therapy in improving CTD-PH outcomes is under investigation, as prognosis and responsiveness to therapy appear to be worse in SSc-associated PH compared with idiopathic pulmonary arterial hypertension. We discuss medical therapies for CTD-associated PH and the role of lung transplantation for patients who fail medical therapy.

Keywords

systemic sclerosis - scleroderma - pulmonary hypertension - pulmonary arterial hypertension - connective tissue disease

Full Text

References

References
1 Badesch DB, Tapson VF, McGoon MD. , et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132 (06) 425-434
2 Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167 (04) 580-586
3 Trad S, Amoura Z, Beigelman C. , et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006; 54 (01) 184-191
4 Launay D, Sitbon O, Le Pavec J. , et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49 (03) 490-500
5 Condliffe R, Kiely DG, Peacock AJ. , et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179 (02) 151-157
6 Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52 (07) 2125-2132
7 Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130 (01) 182-189
8 Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29 (02) 282-287
9 Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 1999; 26 (09) 1923-1929
10 Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 2006; 25 (06) 866-872
11 Simonson JS, Schiller NB, Petri M, Hellmann DB. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989; 16 (07) 918-925
12 Hunzelmann N, Genth E, Krieg T. , et al; Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47 (08) 1185-1192
13 Lynch III JP, Belperio JA, Saggar R, Fishbein MC, Saggar R. Pulmonary hypertension complicating connective tissue disease. Semin Respir Crit Care Med 2013; 34 (05) 581-599
14 Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360 (19) 1989-2003
15 Ferri C, Valentini G, Cozzi F. , et al; Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81 (02) 139-153
16 Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23 (05) 581-590
17 LeRoy EC, Black C, Fleischmajer R. , et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15 (02) 202-205
18 Denton CP, Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev 2011; 20 (122) 270-276
19 Mukerjee D, St George D, Coleiro B. , et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62 (11) 1088-1093
20 Steen V. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum 2005; 52 (12) 3698-3700
21 Hachulla E, Gressin V, Guillevin L. , et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52 (12) 3792-3800
22 Hachulla E, de Groote P, Gressin V. , et al; Itinér AIR-Sclérodermie Study Group. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60 (06) 1831-1839
23 Launay D, Mouthon L, Hachulla E. , et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007; 34 (05) 1005-1011
24 Vonk MC, Broers B, Heijdra YF. , et al. Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 2009; 68 (06) 961-965
25 Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger Jr TA. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007; 34 (01) 104-109
26 Muangchan C, Baron M, Pope J. ; Canadian Scleroderma Research Group. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol 2013; 40 (09) 1545-1556
27 Tyndall AJ, Bannert B, Vonk M. , et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69 (10) 1809-1815
28 Volkmann ER, Furst DE. Management of systemic sclerosis-related skin disease: a review of existing and experimental therapeutic approaches. Rheum Dis Clin North Am 2015; 41 (03) 399-417
29 Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010; 37 (01) 42-53
30 Sato H, Lagan AL, Alexopoulou C. , et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 2004; 50 (02) 558-564
31 Weiner ES, Earnshaw WC, Senécal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 1988; 31 (03) 378-385
32 Joyal F, Choquette D, Roussin A, Levington C, Senécal JL. Evaluation of the severity of systemic sclerosis by nailfold capillary microscopy in 112 patients. Angiology 1992; 43 (3, Pt 1): 203-210
33 Maricq HR, Spencer-Green G, LeRoy EC. Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med 1976; 61 (06) 862-870
34 LeRoy EC, Medsger Jr TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28 (07) 1573-1576
35 van den Hoogen F, Khanna D, Fransen J. , et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65 (11) 2737-2747
36 Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011; 40 (02) 78-83
37 Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43 (11) 2437-2444
38 Sacks DG, Okano Y, Steen VD, Curtiss E, Shapiro LS, Medsger Jr TA. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 1996; 23 (04) 639-642
39 Penn H, Howie AJ, Kingdon EJ. , et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100 (08) 485-494
40 Poormoghim H, Lucas M, Fertig N, Medsger Jr TA. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43 (02) 444-451
41 Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990; 21 (05) 467-474
42 Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29 (02) 239-254
43 Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37 (04) 223-235
44 Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66 (07) 940-944
45 Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 2004; 43 (09) 1129-1137
46 Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012; 24 (02) 165-170
47 Satoh M, Akizuki M, Kuwana M. , et al. Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma. J Rheumatol 1994; 21 (01) 111-114
48 Nishioka K, Katayama I, Kondo H. , et al; Scleroderma Research Committee Japan. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). J Dermatol 1996; 23 (10) 677-682
49 Makino S, Fujiwara M, Handa H. , et al. Plasma dehydroepiandrosterone sulphate and insulin-like growth factor I levels in obstructive sleep apnoea syndrome. Clin Endocrinol (Oxf) 2012; 76 (04) 593-601
50 Reveille JD, Fischbach M, McNearney T. , et al; GENISOS Study Group. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30 (05) 332-346
51 Agarwal SK, Tan FK, Arnett FC. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008; 34 (01) 17-40, v
52 Rubio-Rivas M, Moreno R, Corbella X. Occupational and environmental scleroderma. Systematic review and meta-analysis. Clin Rheumatol 2017; 36 (03) 569-582
53 Marie I, Gehanno JF, Bubenheim M. , et al. Systemic sclerosis and exposure to heavy metals: a case control study of 100 patients and 300 controls. Autoimmun Rev 2017; 16 (03) 223-230
54 Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42 (12) 2660-2665
55 Elhai M, Wipff J, Bazeli R. , et al. Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2013; 52 (02) 267-275
56 Scussel-Lonzetti L, Joyal F, Raynauld JP. , et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81 (02) 154-167
57 Steen VD, Costantino JP, Shapiro AP, Medsger Jr TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113 (05) 352-357
58 Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB. , et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118 (01) 2-10
59 Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001; 28 (11) 2454-2459
60 Bond C, Pile KD, McNeil JD. , et al. South Australian Scleroderma Register: analysis of deceased patients. Pathology 1998; 30 (04) 386-390
61 Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996; 35 (11) 1122-1126
62 Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37 (01) 75-83
63 Simeón CP, Armadans L, Fonollosa V. , et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42 (01) 71-75
64 Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15 (02) 276-283
65 Lee P, Langevitz P, Alderdice CA. , et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82 (298) 139-148
66 Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger Jr TA, Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999; 42 (03) 465-474
67 Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57 (11) 682-686
68 Kranenburg P, van den Hombergh WM, Knaapen-Hans HK, van den Hoogen FH, Fransen J, Vonk MC. Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology (Oxford) 2016; 55 (11) 2001-2008
69 Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C. , et al; Spanish Scleroderma Study Group (SSSG); Autoimmune Diseases Study Group (GEAS); Spanish Society of Internal Medicine (SEMI). Registry of the Spanish Network for Systemic Sclerosis: Survival, Prognostic Factors, and Causes of Death. Medicine (Baltimore) 2015; 94 (43) e1728
70 Poormoghim H, Andalib E, Jalali A, Ghaderi A, Ghorbannia A, Mojtabavi N. Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran. Rheumatol Int 2016; 36 (07) 925-934
71 Hoffmann-Vold AM, Aaløkken TM, Lund MB. , et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 2015; 67 (08) 2205-2212
72 Czirják L, Kumánovics G, Varjú C. , et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67 (01) 59-63
73 Steen VD, Conte C, Owens GR, Medsger Jr TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37 (09) 1283-1289
74 Steen VD, Powell DL, Medsger Jr TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31 (02) 196-203
75 Reveille JD, Solomon DH. ; American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49 (03) 399-412
76 Hashimoto A, Endo H, Kondo H, Hirohata S. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 2012; 22 (02) 272-279
77 Fanning GC, Welsh KI, Bunn C, Du Bois R, Black CM. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 1998; 37 (02) 201-207
78 Dick T, Mierau R, Bartz-Bazzanella P. , et al. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 2002; 61 (02) 121-127
79 Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42 (04) 534-540
80 Hietarinta M, Lassila O, Hietaharju A. Association of anti-U1RNP- and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). Scand J Rheumatol 1994; 23 (02) 64-67
81 Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5 (02) 80-93
82 Okano Y, Steen VD, Medsger Jr TA. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993; 119 (10) 1005-1013
83 Bose N, Chiesa-Vottero A, Chatterjee S. Scleroderma renal crisis. Semin Arthritis Rheum 2015; 44 (06) 687-694
84 Steen V, Medsger Jr TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48 (02) 516-522
85 Okano Y, Steen VD, Medsger Jr TA. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992; 35 (01) 95-100
86 Fritzler MJ, Hart DA, Wilson D. , et al. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. J Rheumatol 1995; 22 (09) 1688-1693
87 Grigolo B, Mazzetti I, Meliconi R. , et al. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol 2000; 121 (03) 539-543
88 Tamby MC, Chanseaud Y, Humbert M. , et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005; 60 (09) 765-772
89 Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998; 25 (03) 462-466
90 Mitri GM, Lucas M, Fertig N, Steen VD, Medsger Jr TA. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003; 48 (01) 203-209
91 Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 1999; 116 (01) 174-180
92 Tamby MC, Humbert M, Guilpain P. , et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006; 28 (04) 799-807
93 Dorfmüller P, Humbert M, Perros F. , et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38 (06) 893-902
94 Overbeek MJ, Vonk MC, Boonstra A. , et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009; 34 (02) 371-379
95 Cerinic MM, Valentini G, Sorano GG. , et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003; 32 (05) 285-295
96 Le Pavec J, Humbert M, Mouthon L, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 181 (12) 1285-1293
97 Choi JJ, Min DJ, Cho ML. , et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003; 30 (07) 1529-1533
98 McMahan Z, Schoenhoff F, Van Eyk JE, Wigley FM, Hummers LK. Biomarkers of pulmonary hypertension in patients with scleroderma: a case-control study. Arthritis Res Ther 2015; 17: 201
99 Reiseter S, Molberg Ø, Gunnarsson R. , et al. Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. Arthritis Res Ther 2015; 17: 231
100 Distler O, Del Rosso A, Giacomelli R. , et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4 (06) R11
101 Saggar R, Saggar R, Aboulhosn J, Belperio JA, Zisman DA, Lynch III JP. Diagnosis and hemodynamic assessment of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30 (04) 399-410
102 Galiè N, Hoeper MM, Humbert M. , et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30 (20) 2493-2537
103 D'Alonzo GE, Barst RJ, Ayres SM. , et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115 (05) 343-349
104 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351 (14) 1425-1436
105 Fisher MR, Mathai SC, Champion HC. , et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54 (09) 3043-3050
106 Galiè N, Torbicki A, Barst R. , et al; The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25 (24) 2243-2278
107 Mukerjee D, St George D, Knight C. , et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43 (04) 461-466
108 Arcasoy SM, Christie JD, Ferrari VA. , et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167 (05) 735-740
109 Tei C, Dujardin KS, Hodge DO. , et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996; 9 (06) 838-847
110 Miller D, Farah MG, Liner A, Fox K, Schluchter M, Hoit BD. The relation between quantitative right ventricular ejection fraction and indices of tricuspid annular motion and myocardial performance. J Am Soc Echocardiogr 2004; 17 (05) 443-447
111 Forfia PR, Fisher MR, Mathai SC. , et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174 (09) 1034-1041
112 Grünig E, Janssen B, Mereles D. , et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 2000; 102 (10) 1145-1150
113 Alkotob ML, Soltani P, Sheatt MA. , et al. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest 2006; 130 (01) 176-181
114 Condliffe R, Radon M, Hurdman J. , et al. CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology (Oxford) 2011; 50 (08) 1480-1486
115 Khanna D, Gladue H, Channick R. , et al; Scleroderma Foundation and Pulmonary Hypertension Association. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 2013; 65 (12) 3194-3201
116 Schreiber BE, Valerio CJ, Keir GJ. , et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum 2011; 63 (11) 3531-3539
117 Meune C, Avouac J, Airò P. , et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011; 63 (09) 2790-2796
118 Williams MH, Handler CE, Akram R. , et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27 (12) 1485-1494
119 Mathai SC, Bueso M, Hummers LK. , et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010; 35 (01) 95-104
120 Coghlan JG, Denton CP, Grünig E. , et al; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73 (07) 1340-1349
121 Soukup T, Pudil R, Kubinova K. , et al. Application of the DETECT algorithm for detection of risk of pulmonary arterial hypertension in systemic sclerosis: data from a Czech tertiary centre. Rheumatology (Oxford) 2016; 55 (01) 109-114
122 MacGregor AJ, Canavan R, Knight C. , et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40 (04) 453-459
123 Murata I, Kihara H, Shinohara S, Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J 1992; 56 (10) 983-991
124 Battle RW, Davitt MA, Cooper SM. , et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110 (06) 1515-1519
125 Yamane K, Ihn H, Asano Y. , et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology (Oxford) 2000; 39 (11) 1269-1271
126 Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33 (02) 269-274
127 Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004; 63 (09) 1009-1014
128 Plastiras SC, Karadimitrakis SP, Kampolis C, Moutsopoulos HM, Tzelepis GE. Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum 2007; 36 (06) 392-396
129 Cox SR, Walker JG, Coleman M. , et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005; 35 (01) 28-33
130 Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124 (06) 2098-2104
131 Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62 (02) 97-99
132 Ong YY, Nikoloutsopoulos T, Bond CP, Smith MD, Ahern MJ, Roberts-Thomson PJ. Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 1998; 16 (2-3): 81-86
133 Steen VD, Graham G, Conte C, Owens G, Medsger Jr TA. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35 (07) 765-770
134 Steen V, Chou M, Shanmugam V, Mathias M, Kuru T, Morrissey R. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008; 134 (01) 146-151
135 Allanore Y, Borderie D, Avouac J. , et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58 (01) 284-291
136 Visovatti SH, Distler O, Coghlan JG. , et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther 2014; 16 (06) 493
137 Hinchcliff M, Fischer A, Schiopu E, Steen VD. ; PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011; 38 (10) 2172-2179
138 Hsu VM, Chung L, Hummers LK. , et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum 2014; 44 (01) 55-62
139 Hachulla E, Carpentier P, Gressin V. , et al; ItinérAIR-Sclérodermie Study Investigators. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology (Oxford) 2009; 48 (03) 304-308
140 Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123 (02) 344-350
141 Mathai SC, Hummers LK, Champion HC. , et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60 (02) 569-577
142 Volkmann ER, Saggar R, Khanna D. , et al. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol 2014; 66 (07) 1900-1908
143 Hassoun PM. Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev Respir Med 2009; 3 (02) 187-196
144 Preston IR, Roberts KE, Miller DP. , et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation 2015; 132 (25) 2403-2411
145 Chung L, Liu J, Parsons L. , et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138 (06) 1383-1394
146 Chung L, Farber HW, Benza R. , et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014; 146 (06) 1494-1504
147 Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142 (02) 448-456
148 Clements PJ, Tan M, McLaughlin VV. , et al; Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012; 71 (02) 249-252
149 Meier FM, Frommer KW, Dinser R. , et al; EUSTAR Co-authors. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012; 71 (08) 1355-1360
150 Hachulla E, Clerson P, Airò P. , et al; EUSTAR co-workers. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology (Oxford) 2015; 54 (07) 1262-1269
151 Thompson AE, Pope JE. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol 1998; 37 (12) 1320-1323
152 Hinderliter AL, Willis IV PW, Long W. , et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension. Am J Cardiol 1999; 84 (04) 481-484 , A10
153 Forfia PR, Mathai SC, Fisher MR. , et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177 (12) 1364-1369
154 Williams MH, Das C, Handler CE. , et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92 (07) 926-932
155 Campo A, Mathai SC, Le Pavec J. , et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182 (02) 252-260
156 Ramjug S, Hussain N, Hurdman J. , et al. Idiopathic and systemic sclerosis associated pulmonary arterial hypertension: a comparison of demographic, haemodynamic and magnetic resonance imaging characteristics and outcomes. Chest 2017; 152: 92-102
157 Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfá ES, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003; 9 (04) 311-317
158 Overbeek MJ, Lankhaar JW, Westerhof N. , et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008; 31 (06) 1160-1166
159 Launay D, Humbert M, Berezne A. , et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011; 140 (04) 1016-1024
160 Olschewski H, Ghofrani HA, Walmrath D. , et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160 (02) 600-607
161 Le Pavec J, Girgis RE, Lechtzin N. , et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011; 63 (08) 2456-2464
162 Galiè N, Corris PA, Frost A. , et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D60-D72
163 Galiè N, Humbert M, Vachiery JL. , et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (01) 67-119
164 Taichman DB, Ornelas J, Chung L. , et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 2014; 146 (02) 449-475
165 Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30 (04) 394-403
166 Hachulla E, Launay D, Yaici A. , et al; French PAH-SSc Network. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology (Oxford) 2010; 49 (05) 940-944
167 Fischer A, Bull TM, Steen VD. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken) 2012; 64 (03) 303-310
168 Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67 (06) 808-814
169 Humbert M, Simonneau G. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nat Clin Pract Rheumatol 2005; 1 (02) 93-101
170 Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol 2006; 33 (01) 61-68
171 Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005; 24 (10) 1626-1631
172 Badesch DB, Hill NS, Burgess G. , et al; SUPER Study Group. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007; 34 (12) 2417-2422
173 Oudiz RJ, Schilz RJ, Barst RJ. , et al; Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126 (02) 420-427
174 Barst RJ, Rubin LJ, Long WA. , et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334 (05) 296-301
175 Simonneau G, Barst RJ, Galie N. , et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (06) 800-804
176 McLaughlin VV, Gaine SP, Barst RJ. , et al; Treprostinil Study Group. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 41 (02) 293-299
177 Strauss WL, Edelman JD. Prostanoid therapy for pulmonary arterial hypertension. Clin Chest Med 2007; 28 (01) 127-142 , ix
178 Kallen AJ, Lederman E, Balaji A. , et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 2008; 29 (04) 342-349
179 McGuire F, Kennelly T, Tillack T, Robbins M. Pulmonary capillary hemangiomatosis associated with CREST syndrome: a case report and review of the literature. Respiration 2010; 80 (05) 435-438
180 Gugnani MK, Pierson C, Vanderheide R, Girgis RE. Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis. Arthritis Rheum 2000; 43 (03) 699-703
181 Hoeper MM, Galiè N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165 (09) 1209-1216
182 Launay D, Hachulla E, Hatron PY. , et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol 2001; 28 (10) 2252-2256
183 Tapson VFJZ, Jing ZC, Xu KF. , et al; FREEDOM-C2 Study Team. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013; 144 (03) 952-958
184 Tapson VFTF, Torres F, Kermeen F. , et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142 (06) 1383-1390
185 Channick RN, Simonneau G, Sitbon O. , et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358 (9288): 1119-1123
186 Rubin LJ, Badesch DB, Barst RJ. , et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (12) 896-903
187 Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65 (10) 1336-1340
188 Galiè N, Olschewski H, Oudiz RJ. , et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117 (23) 3010-3019
189 Pulido T, Adzerikho I, Channick RN. , et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369 (09) 809-818
190 Rosato E, Molinaro I, Borghese F, Rossi C, Pisarri S, Salsano F. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol 2010; 37 (12) 2531-2539
191 Korn JH, Mayes M, Matucci Cerinic M. , et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50 (12) 3985-3993
192 Jain M, Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 2006; 7 (11) 1487-1501
193 Matucci-Cerinic M, Denton CP, Furst DE. , et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70 (01) 32-38
194 Galiè N, Ghofrani HA, Torbicki A. , et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353 (20) 2148-2157
195 Galiè N, Brundage BH, Ghofrani HA. , et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119 (22) 2894-2903
196 Galiè N, Barberà JA, Frost AE. , et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373 (09) 834-844
197 Simonneau G, Rubin LJ, Galiè N. , et al; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149 (08) 521-530
198 Keogh A, Strange G, Kotlyar E. , et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern Med J 2011; 41 (03) 235-244
199 Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35 (10) 989-993
200 Lammi MR, Mathai SC, Saketkoo LA. , et al; Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Investigators. Association between initial oral therapy and outcomes in systemic sclerosis-related pulmonary arterial hypertension. Arthritis Rheumatol 2016; 68 (03) 740-748
201 Hassoun PM, Zamanian RT, Damico R. , et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192 (09) 1102-1110
202 Barst RJ, Gibbs JS, Ghofrani HA. , et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S78-S84
203 Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70 (04) 580-587
204 Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112 (03) 714-721
205 Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006; 28 (05) 999-1004
206 Olsson KM, Delcroix M, Ghofrani HA. , et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129 (01) 57-65
207 Ghofrani HA, Galiè N, Grimminger F. , et al; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369 (04) 330-340
208 Humbert M, Coghlan JG, Ghofrani HA. , et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76 (02) 422-426
209 Sitbon O, Channick R, Chin KM. , et al; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373 (26) 2522-2533
210 Duggan ST, Keam SJ, Burness CB. Selexipag: a review in pulmonary arterial hypertension. Am J Cardiovasc Drugs 2017; 17 (01) 73-80
211 Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61 (08) 736
212 Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353 (13) 1412-1413
213 Hoeper MM, Barst RJ, Bourge RC. , et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127 (10) 1128-1138
214 Wang YY, Yang YX, Zhe H, He ZX, Zhou SF. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Des Devel Ther 2014; 8: 2075-2088
215 Barst RJ, McGoon M, McLaughlin V. , et al; Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41 (12) 2119-2125
216 Saggar R, Khanna D, Furst DE. , et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J 2010; 36 (04) 893-900
217 Schachna L, Medsger Jr TA, Dauber JH. , et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54 (12) 3954-3961
218 Christie JD, Edwards LB, Kucheryavaya AY. , et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult lung and heart-lung transplant report--2011. J Heart Lung Transplant 2011; 30 (10) 1104-1122
219 Shitrit D, Amital A, Peled N. , et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant 2009; 23 (02) 178-183
220 Arnett FC, Howard RF, Tan F. , et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 1996; 39 (08) 1362-1370
221 Austin ED, Loyd JE, Phillips III JA. Genetics of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30 (04) 386-398
222 Newman JH, Wheeler L, Lane KB. , et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345 (05) 319-324
223 Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002; 29 (11) 2379-2381
224 Tanoue LT. Pulmonary hypertension in the collagen vascular diseases. Semin Respir Crit Care Med 2003; 24 (03) 287-296
225 Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide MV, Aguirre C. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 2013; 12 (03) 410-415
226 Humbert M, Sitbon O, Chaouat A. , et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173 (09) 1023-1030
227 Bresser P, Pepke-Zaba J, Jaïs X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc 2006; 3 (07) 594-600
228 Li M, Wang Q, Zhao J. , et al; CSTAR co-authors. Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus 2014; 23 (10) 1085-1091
229 Goupille P, Fauchier L, Babuty D, Fauchier JP, Valat JP. Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus. J Rheumatol 1994; 21 (10) 1976-1977
230 Cefle A, Inanc M, Sayarlioglu M. , et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 2011; 31 (02) 183-189
231 Foïs E, Le Guern V, Dupuy A, Humbert M, Mouthon L, Guillevin L. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exp Rheumatol 2010; 28 (06) 836-841
232 Lian F, Chen D, Wang Y. , et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int 2012; 32 (06) 1727-1731
233 Prabu A, Patel K, Yee CS. , et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) 2009; 48 (12) 1506-1511
234 Heresi GA, Minai OA. Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy. Respir Med 2007; 101 (10) 2099-2107
235 Kommireddy S, Bhyravavajhala S, Kurimeti K. , et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. Rheumatology (Oxford) 2015; 54 (09) 1673-1679
236 Huang C, Zhang S, Tian Z, Li M, Zeng X. Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus? A successful case of SLE-PAH cured by methylprednisolone pulse therapy. Lupus 2014; 23 (14) 1533-1536
237 Gonzalez-Lopez L, Cardona-Muñoz EG, Celis A. , et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004; 13 (02) 105-112
238 Gunnarsson R, Andreassen AK, Molberg Ø. , et al. Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology (Oxford) 2013; 52 (07) 1208-1213
239 Kang KY, Jeon CH, Choi SJ. , et al. Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension by echocardiography: results from a Korean nationwide registry. Int J Rheum Dis 2015;
240 Sullivan WD, Hurst DJ, Harmon CE. , et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984; 63 (02) 92-107
241 Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42 (05) 899-909
242 Alpert MA, Goldberg SH, Singsen BH. , et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 1983; 68 (06) 1182-1193
243 Jais X, Launay D, Yaici A. , et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58 (02) 521-531